Mergers & Acquisitions ·
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals and concurrently entered into a $132…
JSPRJasper Therapeutics, Inc.
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals and concurrently entered into a $132 million private placement of non-voting convertible preferred stock. The transaction includes an out-licensing deal for KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront and potential milestones. Jasper Therapeutics is a clinical-stage biotechnology company developing biologic agents for immunologically-driven disorders.